Protagen Completes $5.3M Funding Round | GenomeWeb

NEW YORK (GenomeWeb News) – Protagen has received €3.7 million ($5.3 million) in funding from existing institutional European investors, the company said today.

The company plans to use the funding to expand its UNIarray technology and patent position and to clinically validate proprietary diagnostic marker proteins. These efforts will focus on developing serum-based molecular diagnostic tests for early detection of multiple sclerosis and for differential diagnosis of prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.